Penicillamine induced polymyositis and dermatomyositis

J Rheumatol. 1987 Oct;14(5):995-1001.

Abstract

Eight Australian cases of D-penicillamine induced polymyositis/dermatomyositis (PM/DM) are reported. In terms of clinical, pathological and electromyographic features, D-penicillamine PM/DM is similar to idiopathic PM/DM but is generally less severe. Recovery is usually rapid when D-penicillamine is withdrawn. Sera were available for study in 6 of the 8 reported cases. Two of the 6 had elevated titers of acetylcholine receptor autoantibodies. Neither of these patients had clinical signs of myasthenia gravis. In 3 of 6 patients typed for C2, no bands were detected suggesting homozygous C2 deficiency. D-penicillamine PM/DM is associated with HLA-B18, B35 and DR4 and is immunogenetically different from idiopathic PM/DM, rheumatoid arthritis and D-penicillamine myasthenia gravis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antibodies, Antinuclear / analysis
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / immunology
  • Autoantibodies / analysis
  • Dermatomyositis / chemically induced*
  • Dermatomyositis / immunology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis / chemically induced
  • Myasthenia Gravis / immunology
  • Myositis / chemically induced*
  • Myositis / immunology
  • Penicillamine / adverse effects*
  • Penicillamine / therapeutic use
  • Receptors, Cholinergic / immunology

Substances

  • Antibodies, Antinuclear
  • Autoantibodies
  • Receptors, Cholinergic
  • Penicillamine